Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients

OBJECTIVES: Teriflunomide, a disease‐modifying treatment approved for multiple sclerosis (MS), inhibits reversibly dihydroorotate dehydrogenase, an enzyme involved in de novo pyrimidine biosynthesis and down‐regulates proliferation of activated lymphocytes. We aimed to study the impact of this drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Medina, Silvia, Sainz de la Maza, Susana, Villarrubia, Noelia, Álvarez‐Lafuente, Roberto, Costa‐Frossard, Lucienne, Arroyo, Rafael, Monreal, Enric, Tejeda‐Velarde, Amalia, Rodríguez‐Martín, Eulalia, Roldán, Ernesto, Álvarez‐Cermeño, José C., Villar, Luisa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389853/
https://www.ncbi.nlm.nih.gov/pubmed/30847367
http://dx.doi.org/10.1002/acn3.711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389853/
https://www.ncbi.nlm.nih.gov/pubmed/30847367
http://dx.doi.org/10.1002/acn3.711

Ejemplares similares